# LACTIC ACID (lactic-acid) — Global Cosmetic Regulatory & Formulation Monograph - **Canonical URL**: https://www.inciname.com/en/ingredients/lactic-acid - **Standard INCI**: `LACTIC ACID` - **KR MFDS Standard Name**: `락틱애씨드` - **CAS No.**: `50-21-5` - **EC / EINECS No.**: `200-018-0` - **Origin**: `synthetic` - **Functions**: pH조절제, 보습제, 피부컨디셔닝제, 완충제 - **Molecular Formula / MW**: `—` (— g/mol) ## 1. 7-Track Official Regulatory Label Names | Track | Official Label Nomenclature | | :--- | :--- | | KR (MFDS Standard) | 락틱애씨드 | | KR (Former Names) | — | | EU (CosIng 1223/2009) | LACTIC ACID | | US (PCPC / MoCRA INCI) | LACTIC ACID | | US (FDA OTC Monograph) | — | | CN (NMPA IECIC) | 乳酸 | | JP (JCIA / MHLW QD) | 乳酸 (QD: 乳酸) | ## 2. Layer 1 — Global 6-Region Statutory Summary - **KR (MFDS)**: `none` - **EU (1223/2009)**: `none` - **US (FDA/MoCRA)**: `none` - **CN (NMPA IECIC)**: `allowed` (Entry: `5649`) - **JP (MHLW)**: `none` - **ASEAN (ACD)**: `none` ## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations - **cn_iecic_max** (leave_on): ≤ 6% — NMPA IECIC (2025) Entry 05688 (2025) - **cn_iecic_max** (rinse_off): ≤ 6% — NMPA IECIC (2025) Entry 05688 (2025) ## 4. Layer 3 — Formulation Quartiles & Compatibility - **Optimal pH Window**: 4 – 8 - **Max Process Temp**: ≤ 50°C - **Synergy Pairings**: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL - **Incompatibilities**: Verify phase compatibility under extreme pH or high electrolyte loads ## 5. Academic Monograph ■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: LACTIC ACID | CAS No.: 50-21-5 | EC No.: 200-018-0 - Origin: SYNTHETIC | Functions: pH, , , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [LACTIC ACID] · EU [LACTIC ACID] · CN [乳酸] · JP [乳酸] · JP Quasi-Drug [乳酸] ■ [2. Dermatological Mechanism of Action & Functional Role] - LACTIC ACID functions primarily as pH, , , in dermatological and cosmetic formulations. Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver pH, , , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 5649 (乳酸)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 6.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 6.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 0.1 ~ 0.9% (Median 0.6%, Ref: Global Starter Formulation Library Statistical Distribution (n=7, GRANT 6 · SEPPIC 1)) — Emulsion cream & lotion structural / conditioning agent ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: LACTIC ACID ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 42317277 (2026, Food Chem X): Deep eutectic solvent-mediated extraction of collagen peptides from sturgeon skin: Molecular-weight control and mechanis - PMID 42303762 (2026, Aesthetic Plast Surg): PLLA Microspheres Regulate Adipocyte Dedifferentiation via Lactate: A Novel Strategy for Fat Graft Survival Enhancement - PMID 42296811 (2026, J Hazard Mater): Organic acids enhanced the phototransformation of 1-nitronaphthalene in skin sweat: The critical role of carbon-centered ## 6. Linked PubMed Literature - [PMID: 42317277] Deep eutectic solvent-mediated extraction of collagen peptides from sturgeon skin: Molecular-weight control and mechanistic insights — *Food Chem X* (2026) - [PMID: 42303762] PLLA Microspheres Regulate Adipocyte Dedifferentiation via Lactate: A Novel Strategy for Fat Graft Survival Enhancement — *Aesthetic Plast Surg* (2026) - [PMID: 42296811] Organic acids enhanced the phototransformation of 1-nitronaphthalene in skin sweat: The critical role of carbon-centered radicals — *J Hazard Mater* (2026) - [PMID: 42278462] Comparative ESEM Characterization and Collagen-Related Tissue Responses to Commercial Injectable Bioregenerative Formulations in a Murine Model — *Int J Mol Sci* (2026) - [PMID: 42235050] Safety and Effectiveness of Two Reconstitution Volumes of Poly-L-Lactic Acid for Correction of Décolletage Wrinkles — *J Drugs Dermatol* (2026) - [PMID: 42210881] Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population — *Dermatol Surg* (2026) - [PMID: 42311585] Type 1 Collagen/Poly-L-Lactic Acid Biocomposite Augmentation of a Nontraumatic Symptomatic Complete Rotator Cuff Tear — *Ochsner J* (2026) - [PMID: 42299445] VectorLift: Anatomically Guided Thread-Lifting Technique With Reduced Pain and Downtime - Results from a Real-World Non-Randomized Comparative Study — *Clin Cosmet Investig Dermatol* (2026) - [PMID: 42253424] Longevity Aesthetics: A Conceptual Framework for Integrating Pro-Aging Medicine Into Surgical and Nonsurgical Practice — *Aesthet Surg J Open Forum* (2026) - [PMID: 42211639] Mechanisms of Cytokine Modulation and Inflammatory Cascade in Bio-stimulatory Skin Rejuvenation: A Comprehensive Literature Review of Poly-L-Lactic Acid, Calcium Hydroxyapatite, Polycaprolactone, and Poly-D, L-Lactic Acid — *Cureus* (2026) - [PMID: 42205557] Controlled release of chlorine dioxide from α-cyclodextrin complexes embedded in poly(lactic acid)/poly(butylene adipate-co-butylene terephthalate) films for sustainable food packaging — *Food Chem X* (2026) - [PMID: 42199246] Dual-mode Sequential Radiofrequency in Challenging Skin Types: Case Reports in Atopic-prone and Previously Treated Patients — *Plast Reconstr Surg Glob Open* (2026)